Schedule 13G ownership disclosure

Vistagen Therapeutics Inc

Common Stock, par value $0.001 per share · CUSIP: 92840H400

Event date: 2025-09-30

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • ORBIMED ADVISORS LLC

    Shares: 1,420,300.00 · Class: 4.63%

  • ORBIMED CAPITAL LLC

    Shares: 1,639,700.00 · Class: 5.34%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000947871-25-001019
Form type
SCHEDULE 13G
Filer
ORBIMED ADVISORS LLC
CIK
CIK 1055951
Filed
Nov 14, 2025
Reporting period
Sep 30, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub